Article

Study partner profile effects on CDR-SB change in anti-amyloid therapy evaluation

2026-06-24

Abstract excerpt

<h4>INTRODUCTION</h4> The Clinical Dementia Rating Sum of Boxes (CDR-SB), a primary outcome in anti-amyloid therapy (AAT) trials, integrates information from participants and study partners. CDR-SB scores may vary by study partner characteristics, but their impact on 18-month change interpretation remains unclear. <h4>METHODS</h4> Using the NACC Uniform Data Set, we fitted linear mixed-effects calibration models...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 2a6c4536-3b75-5a23-864f-152d10e19e38
DOI: 10.64898/2026.06.22.26356066

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Study partner profile effects on CDR-SB change in anti-amyloid therapy evaluationDOI 10.64898/2026.06.22.26356066Read

Mapping U.S. POINTER Cognitive-Slope Gains Onto Predicted Clinical Progression: An External-Cohort Translation Analysis With Exploratory Economic ThresholdsSemantic proximity Read

Tau-Clinical Mismatch Identifies Individuals with Co-Pathology and Predicts Clinical TrajectorySemantic proximity Read

Use of preclinical Alzheimer’s disease trajectories for clinical trial designSemantic proximity Read

An updated Alzheimer's disease progression model: incorporating non-linearity, beta regression, and a third-level random effect in NONMEM.Semantic proximity Read

PET and CSF amyloid-β status are differently predicted by patient features: Information from discordant casesSemantic proximity Read

Equity and Transportability of Plasma ATN Phenotypes in a Population-Representative U.S. Aging CohortSemantic proximity Read

Consensus Risk Modeling and Uncertainty Quantification of Alzheimer’s Disease Using 5ADCSI Plasma Biomarkers and Multiple External Machine-Learning FrameworksSemantic proximity Read

Generalizability of trial criteria on amyloid-lowering therapy against Alzheimer’s disease to individuals with MCI or early AD in the general populationSemantic proximity Read

MMSE-CDR-SB residual as an exploratory indicator of deviation from an Alzheimer’s disease-typical cognitive-functional patternSemantic proximity Read

A data-driven Alzheimer’s disease progression simulator for retrospective validation and prospective Phase III power designSemantic proximity Read

Cross-Cohort Generalizability of Plasma Biomarker Machine Learning Models Reveals Calibration-Driven Degradation in Clinical UtilitySemantic proximity Read

Design-Induced Circularity in Alzheimer’s Biomarker Trials and Trial-Ready Cohorts: Enrichment, Data-Driven Selection, and Estimand MismatchSemantic proximity Read